Mercer Global Advisors
TBPH icon

Mercer Global Advisors’s Theravance Biopharma TBPH Stock Holding History

Mercer Global Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$304K Buy
17,908
+5,291
+42% +$87.6K ﹤0.01% 2789
2026
Q1 		$205K Buy
+12,617
New +$223K ﹤0.01% 2817

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Mercer Global Advisors's TBPH Position: Q2 2026 in Review

Mercer Global Advisors increased its Theravance Biopharma (TBPH) stake by 42% in Q2 2026, buying an estimated $87.6K and bringing the position to 17,908 shares worth $304K. The position accounts for ﹤0.01% of the portfolio, ranked #2789.

Mercer Global Advisors first reported a position in TBPH in Q1 2026 and has held it in 2 quarters since. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Mercer Global Advisors held 17,908 shares of Theravance Biopharma worth $304K as of Q2 2026.
  • Mercer Global Advisors bought 5,291 Theravance Biopharma shares in Q2 2026, an estimated $87.6K.
  • Theravance Biopharma made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2789 holding.
  • Mercer Global Advisors first reported a position in Theravance Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.